Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of iEvac-Z Ebola vaccine in healthy adult men
jRCTs031190118Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2019
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Adverse events and Safety laboratory and inspection indices. Started Nov 2019; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on jRCTs031190118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190118.